News
MBX
55.94
+2.62%
1.43
Nvidia downgraded, AMD upgraded: Wall Street’s top analyst calls
TipRanks · 2d ago
This Kimball Electronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 2d ago
MBX Biosciences Price Target Announced at $90.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
MBX Biosciences Initiated at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
MBX Biosciences initiated with a Buy at H.C. Wainwright
TipRanks · 2d ago
HC Wainwright & Co. Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $90
Benzinga · 2d ago
MBX Biosciences, Inc. (MBX) Receives a Buy from Stifel Nicolaus
TipRanks · 3d ago
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
TipRanks · 3d ago
MBX Biosciences (MBX) Starts Phase 3 Trial, Is The Stock Still A Bargain?
Simply Wall St · 4d ago
UBS Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)
TipRanks · 4d ago
Bigger Losses Could Test The Case For MBX Biosciences Stock
Simply Wall St · 5d ago
MBX Biosciences Reports Progress in Pivotal Phase 3 Trial
TipRanks · 5d ago
MBX Biosciences GAAP EPS of -$1.29
Seeking Alpha · 5d ago
Press Release: MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
Dow Jones · 5d ago
*MBX Biosciences 3Q Loss/Shr $1.29 >MBX
Dow Jones · 5d ago
Weekly Report: what happened at MBX last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at MBX last week (1026-1030)?
Weekly Report · 11/02 09:43
Oppenheimer's top 50 small- and mid-cap Buy list
Seeking Alpha · 10/26 16:59
Weekly Report: what happened at MBX last week (1019-1023)?
Weekly Report · 10/26 09:42
MBX Biosciences Expands Board, Appoints New Director
TipRanks · 10/22 12:28
More
Webull provides a variety of real-time MBX stock news. You can receive the latest news about MBX Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About MBX
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.